Antitrypanosomal activity of a new triazine derivative, SIPI 1029, in vitro and in model infections

A recently developed diaminotriazine derivative [O,O '-bis( 1,2-dihydro-2,2-tetramethylene-4,6-diamino-S- triazin-1-yl)-1,6-hexanediol dihydrochloride; T-46; SIPI 1029] was examined for activity against African trypanosomes in in vitro and in vivo model systems, In vitro, SIPI 1029 was 50% inhibitory for growth of bloodstream trypomastigotes of four strains of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense at 0.15 to 2.15 nhl (50% inhibitory concentrations). In in vivo mouse laboratory models of T. b. rhodesiense clinical isolate infections, SIPI 1029 was curative for 12 of 13 isolates at less than or equal to 10 mg/kg of body weight/day for 3 days, In eight infections, a single dose was greater than or equal to 60% curative, and in six of these, a dose of less than or equal to 5 mg/kg was sufficient for greater than or equal to 60% cure rates. A number of these isolates were resistant to the standard trypanocide melarsoprol (Arsobal) and/or the diamidines diminazene aceturate (Berenil) and pentamidine, SIPI 1029 was also curative in combination with DL-alpha-difluoromethylornithine (Ornidyl) in a T, b, brucei central nervous system model infection, Some evidence of toxicity was found in dosage regimens of 10 mg/kg/day for 2 or 3 days in which deaths were observed in 6 of 65 animals given this dosage regimen. The activity of SIPI 1029 in this study indicates that this class of compounds (diaminotriazines) should be explored as leads for new human and veterinary trypanocides.